Investigational Treatments for Hidradenitis Suppurativa
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What evidence supports the effectiveness of the drugs CFZ533, LOU064, Remibrutinib, LOU-064, LOU064-NXA, NVP-LOU064-NXA, LYS006, MAS825 for treating hidradenitis suppurativa?
Research suggests that drugs targeting the IL-17 pathway, like secukinumab and brodalumab, have shown effectiveness in treating hidradenitis suppurativa, with a significant number of patients responding positively. This indicates that treatments affecting similar pathways may also be promising for this condition.12345
What is the purpose of this trial?
The main purpose of this study is to assess preliminary efficacy and safety of CFZ533, LYS006, MAS825 , LOU064 and VAY736 in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LYS006, MAS825, LOU064 and VAY736 have an adequate clinical profile for further clinical development.
Eligibility Criteria
This trial is for individuals over 50 kg with moderate to severe Hidradenitis Suppurativa. Participants must be able to follow the study's procedures and visit schedule. Pregnant or breastfeeding women, or those who can become pregnant and are not using effective contraception, cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive investigational drugs or placebo for 16 weeks to assess efficacy and safety
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- CFZ533
- LOU064
- LYS006
- MAS825
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD